

【Therapeutic category】 625 Anti-virus agents
【Non-proprietary name】 Lenacapavir sodium
【Safety measure】 PRECAUTIONS should be revised.

A revised description is underlined.

Current			Revision		
2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)			2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)		
Patients receiving rifampicin, phenytoin, phenytoin/phenobarbital, fosphenytoin sodium hydrate, carbamazepine, apalutamide, enzalutamide, mitotane, food containing St. John's Wort, lomitapide mesilate, methylergometrine maleate, and ergotamine tartrate/anhydrous caffeine/isopropylantipyrene			Patients receiving rifampicin, phenytoin, phenytoin/phenobarbital, fosphenytoin sodium hydrate, carbamazepine, apalutamide, enzalutamide, mitotane, <u>encorafenib, ivosidenib</u> , food containing St. John's Wort, lomitapide mesilate, methylergometrine maleate, and ergotamine tartrate/anhydrous caffeine/isopropylantipyrene		
10. INTERACTIONS			10. INTERACTIONS		
10.1 Contraindications for Co-administration (Do not co-administer with the following)			10.1 Contraindications for Co-administration (Do not co-administer with the following)		
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
Rifampicin	Since the plasma	The strong	Rifampicin	Since the plasma	The strong
Phenytoin	concentrations of	CYP3A-, P-gp-, or	Phenytoin	concentrations of	CYP3A-, P-gp-, or

Phenytoin/phenobarbital Fosphenytoin sodium hydrate Carbamazepine Apalutamide Enzalutamide Mitotane	lenacapavir may decrease, the effect of this drug may decrease, and resistance to this drug may develop.	UGT1A1-inducing activity of these drugs may decrease the plasma concentration of this drug.

Phenytoin/phenobarbital Fosphenytoin sodium hydrate Carbamazepine Apalutamide Enzalutamide Mitotane <u>Encorafenib</u> <u>Ivosidenib</u>	lenacapavir may decrease, the effect of this drug may decrease, and resistance to this drug may develop.	UGT1A1-inducing activity of these drugs may decrease the plasma concentration of this drug.
---	--	---

This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.